Cytosorbents Cor (CTSO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,477 | -9,322 | -4,678 | -3,664 | -5,482 |
| Depreciation Amortization | 113 | 264 | 376 | 526 | 985 |
| Accounts receivable | 132 | -412 | -401 | -16 | -36 |
| Other Working Capital | -452 | -608 | 291 | -542 | -197 |
| Other Operating Activity | 637 | 3,797 | 924 | 79 | 902 |
| Operating Cash Flow | $-9,048 | $-6,281 | $-3,489 | $-3,616 | $-3,829 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -248 | -1,945 | N/A | N/A | N/A |
| PPE Investments | -404 | -153 | -39 | -20 | -35 |
| Purchase Sale Intangibles | -240 | -214 | -178 | -19 | -18 |
| Other Investing Activity | -240 | -214 | -178 | -19 | -18 |
| Investing Cash Flow | $-891 | $-2,312 | $-216 | $-39 | $-53 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 1,843 | 700 | 1,250 |
| Common Stock Issued | 2,116 | 266 | 160 | 11 | 5 |
| Other Financing Activity | 9,524 | 9,751 | 2,200 | 3,500 | 2,757 |
| Financing Cash Flow | $11,640 | $10,017 | $4,203 | $4,211 | $4,012 |
| Exchange Rate Effect | 10 | -2 | -43 | -13 | N/A |
| Beginning Cash Position | 3,605 | 2,183 | 1,729 | 1,187 | 1,056 |
| End Cash Position | 5,317 | 3,605 | 2,183 | 1,729 | 1,187 |
| Net Cash Flow | $1,712 | $1,422 | $454 | $543 | $131 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,048 | -6,281 | -3,489 | -3,616 | -3,829 |
| Capital Expenditure | -404 | -153 | -39 | -20 | -35 |
| Free Cash Flow | -9,451 | -6,434 | -3,528 | -3,636 | -3,863 |